Automate Your Wheel Strategy on AXSM
With Tiblio's Option Bot, you can configure your own wheel strategy including AXSM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AXSM
- Rev/Share 10.0124
- Book/Share 1.478
- PB 79.2561
- Debt/Equity 2.9462
- CurrentRatio 1.5686
- ROIC -0.6199
- MktCap 5845461710.0
- FreeCF/Share -2.4374
- PFCF -48.5056
- PE -23.4574
- Debt/Assets 0.3365
- DivYield 0
- ROE -3.5758
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AXSM | Morgan Stanley | -- | Overweight | -- | $190 | July 3, 2025 |
| Initiation | AXSM | Oppenheimer | -- | Outperform | -- | $185 | June 3, 2025 |
| Initiation | AXSM | Jefferies | -- | Buy | -- | $200 | April 7, 2025 |
| Initiation | AXSM | Deutsche Bank | -- | Buy | -- | $176 | Feb. 11, 2025 |
| Reiterated | AXSM | Mizuho | -- | Outperform | $124 | $122 | Dec. 31, 2024 |
| Initiation | AXSM | Wells Fargo | -- | Overweight | -- | $140 | Sept. 3, 2024 |
News
Why Axsome Therapeutics Stock Is Soaring Today
Published: February 11, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Axsome Therapeutics (AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m.
Read More
Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.
Read More
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Why Axsome Therapeutics Stock Is Skyrocketing Today
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Axsome Therapeutics (AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m.
Read More
About Axsome Therapeutics, Inc. (AXSM)
- IPO Date 2015-11-19
- Website https://www.axsome.com
- Industry Biotechnology
- CEO Herriot Tabuteau
- Employees 712